Gilead Sciences (GILD) EBITDA Margin (QoQ) (2009 - 2026)
Gilead Sciences (GILD) EBITDA Margin (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.33 Bn | 630.58 Bn | 17.26 Bn |
| 2 | AbbVie | 469.67 Bn | 463.10 Bn | 12.70 Bn |
| 3 | Merck | 374.13 Bn | 366.99 Bn | 12.21 Bn |
| 4 | Novartis Ag | 302.76 Bn | 295.07 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.15 Bn | 252.25 Bn | 12.86 Bn |
| 6 | Amgen | 236.76 Bn | 222.77 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 182.54 Bn | 179.36 Bn | 6.22 Bn |
| 8 | Pfizer | 159.57 Bn | 147.87 Bn | 10.94 Bn |
| 9 | Gsk | 105.99 Bn | 101.83 Bn | 8.24 Bn |
| 10 | Sanofi | 55.15 Bn | 47.77 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17,036.00 |
| Mar 31, 2026 | 1,212.00 |
| Dec 31, 2025 | -1,779.00 |
| Sep 30, 2025 | 789.00 |
| Jun 30, 2025 | 138.00 |
| Mar 31, 2025 | 116.00 |
| Dec 31, 2024 | 2,063.00 |
| Sep 30, 2024 | -2,625.00 |
| Jun 30, 2024 | 10,266.00 |
| Mar 31, 2024 | -8,730.00 |
| Dec 31, 2023 | -1,454.00 |
| Sep 30, 2023 | 1,197.00 |
| Jun 30, 2023 | -161.00 |
| Mar 31, 2023 | -384.00 |
| Dec 31, 2022 | -961.00 |
| Sep 30, 2022 | 787.00 |
| Jun 30, 2022 | 2,942.00 |
| Mar 31, 2022 | -999.00 |
| Dec 31, 2021 | -3,880.00 |
| Sep 30, 2021 | 1,565.00 |